What is gene therapy for cancer treatment?

Gene therapy for cancer involves modifying immune cells to become cancer killers, like Kymriah, Luxturna, and Zolgensma. These therapies aim to target and destroy cancer cells in the body. However, the high costs and uncertainties surrounding these treatments raise ethical and financial concerns, leading to negotiations between health insurance companies and pharmaceutical firms to determine reimbursement and pricing.

How do health insurance companies negotiate drug prices?

Health insurance companies negotiate drug prices with pharmaceutical firms like Novartis to ensure affordable access to treatments for patients. For example, in the case of Kymriah, health insurance companies like Helsana questioned the therapy's long-term efficacy and pricing rationale, leading to negotiations that resulted in a 20-30% discount for the treatment. These negotiations are crucial in determining the affordability and accessibility of innovative but expensive therapies.

What are the challenges faced by patients with expensive treatments?

Patients like Michael face financial challenges when dealing with expensive treatments like Kymriah, which is priced at 370,000 francs. Some patients may be unable to afford these treatments, leading to a two-tiered healthcare system where access to cutting-edge therapies is limited by financial means. Despite the high costs, treatments like Kymriah offer hope, with a success rate of 40% in patients like Michael, highlighting the complex ethical and financial dilemmas surrounding healthcare access and affordability.

How do pharmaceutical companies determine drug prices?

Pharmaceutical companies determine drug prices based on factors like research and development costs, operational profits, and negotiations with health insurance companies. For example, Novartis created a pricing model for Kymriah based on a $1 billion investment, setting a fair price of $200,000 for 1,700 patients in the USA and Europe. This pricing strategy aims to balance affordability for patients, operational profits for the company, and ongoing research funding for innovative treatments.

What are the ethical concerns surrounding pharmaceutical pricing?

The pharmaceutical industry's pricing practices raise ethical concerns related to transparency, patient access to treatments, and research funding sources. The lack of transparency in pricing strategies, coupled with the high costs of innovative therapies like Kymriah, leads to criticisms from health insurance associations and the public. Negotiations between health insurance companies and pharmaceutical firms play a crucial role in addressing these concerns and ensuring fair pricing that balances patient access, company profits, and research sustainability.

The power of the pharmaceutical companies | DW Documentary

DW Documentary・2 minutes read

Father of two, Michael Monstein, faces aggressive cancer with a prognosis of two to three months; gene therapy offers hope but comes with staggering costs and ethical concerns, with pharmaceutical pricing impacting patient access and health insurance negotiations. Novartis' pricing strategies for Kymriah raise transparency issues, with negotiations leading to discounts, showcasing the evolving landscape of medical advancements, high costs, and uncertainties surrounding cancer treatments.

Insights

Health insurance companies negotiate prices with pharmaceutical firms like Novartis for innovative, costly treatments such as Kymriah, reflecting ongoing challenges in balancing treatment access, pricing transparency, and long-term efficacy concerns in healthcare.
The evolving landscape of medical advancements, exemplified by Kymriah's success in patients like Kurt Benninger, showcases the potential of gene therapy with cancer killer cells while underscoring the uncertainties surrounding long-term effects and the financial burdens patients face, prompting critical discussions on ethical considerations and the sustainability of healthcare systems.

Get key ideas from YouTube videos. It’s free

Recent questions

What is gene therapy for cancer treatment?
Gene therapy for cancer involves modifying immune cells to become cancer killers, like Kymriah, Luxturna, and Zolgensma. These therapies aim to target and destroy cancer cells in the body. However, the high costs and uncertainties surrounding these treatments raise ethical and financial concerns, leading to negotiations between health insurance companies and pharmaceutical firms to determine reimbursement and pricing.
How do health insurance companies negotiate drug prices?
Health insurance companies negotiate drug prices with pharmaceutical firms like Novartis to ensure affordable access to treatments for patients. For example, in the case of Kymriah, health insurance companies like Helsana questioned the therapy's long-term efficacy and pricing rationale, leading to negotiations that resulted in a 20-30% discount for the treatment. These negotiations are crucial in determining the affordability and accessibility of innovative but expensive therapies.
What are the challenges faced by patients with expensive treatments?
Patients like Michael face financial challenges when dealing with expensive treatments like Kymriah, which is priced at 370,000 francs. Some patients may be unable to afford these treatments, leading to a two-tiered healthcare system where access to cutting-edge therapies is limited by financial means. Despite the high costs, treatments like Kymriah offer hope, with a success rate of 40% in patients like Michael, highlighting the complex ethical and financial dilemmas surrounding healthcare access and affordability.
How do pharmaceutical companies determine drug prices?
Pharmaceutical companies determine drug prices based on factors like research and development costs, operational profits, and negotiations with health insurance companies. For example, Novartis created a pricing model for Kymriah based on a $1 billion investment, setting a fair price of $200,000 for 1,700 patients in the USA and Europe. This pricing strategy aims to balance affordability for patients, operational profits for the company, and ongoing research funding for innovative treatments.
What are the ethical concerns surrounding pharmaceutical pricing?
The pharmaceutical industry's pricing practices raise ethical concerns related to transparency, patient access to treatments, and research funding sources. The lack of transparency in pricing strategies, coupled with the high costs of innovative therapies like Kymriah, leads to criticisms from health insurance associations and the public. Negotiations between health insurance companies and pharmaceutical firms play a crucial role in addressing these concerns and ensuring fair pricing that balances patient access, company profits, and research sustainability.

Summary

00:00

High Costs of Cancer Gene Therapy Treatment

Michael Monstein, a father of two, received a sudden diagnosis of aggressive cancer, leading to life-altering changes.
Two chemotherapy treatments failed, leaving him with a prognosis of two to three months if untreated.
His last hope lies in gene therapy with cancer killer cells like Kymriah, Luxturna, and Zolgensma, with staggering costs.
Negotiations between health insurance companies and pharmaceutical firms like Novartis determine reimbursement and pricing.
Kymriah, a new therapy, involves genetically modifying immune cells into cancer killers, priced at 370,000 francs.
Health insurance companies like Helsana negotiate prices with Novartis, questioning the therapy's long-term efficacy and pricing rationale.
The pharmaceutical industry's pricing strategies lack transparency, with health insurance companies facing dilemmas over coverage.
Patients like Michael face financial challenges, with some unable to afford treatments, leading to a two-tiered healthcare system.
Despite the high costs and uncertainties, Kymriah offers hope, with a success rate of 40% in patients like Michael.
The pharmaceutical industry's pricing practices, research funding sources, and patient access to treatments raise ethical and financial concerns.

20:14

"Kymriah Pricing Model and Negotiations Revealed"

Paul Kleutghen was CEO of a company acquired by Novartis in 2002.
Novartis benefited from a 50% tax discount on Kymriah's study costs.
Taxpayers funded part of Kymriah's development.
A pricing model for Kymriah was created based on Novartis' $1 billion investment.
The fair price for Kymriah this year is $200,000 for 1,700 patients in the USA and Europe.
The price can decrease as more patients are treated.
The fair price ensures Novartis achieves a 20.7% operating profit.
Health insurance association Santésuisse demands 200,000 francs for Kymriah.
Transparency criticism towards the pharmaceutical industry is growing.
Negotiations between health insurance companies and Novartis led to a 20-30% discount for Kymriah.

40:00

Kymriah treatment eliminates tumor mass completely

The tumor mass in the muscle box and lower leg disappeared completely without any trace of inflammation after treatment with Kymriah, although the possibility of cancer recurrence cannot be ruled out due to limited data on CAR-T cell treatment rates. Kurt Benninger's cancer also vanished post-treatment, but the long-term effects of the cancer killer cells remain uncertain, highlighting the evolving landscape of medical advancements and the high costs associated with such treatments.

The power of the pharmaceutical companies | DW Documentary

Insights

Get key ideas from YouTube videos. It’s free

Recent questions

Related videos